The current state of retinopathy of prematurity in India, Kenya, Mexico, Nigeria, Philippines, Romania, Thailand, and Venezuela

Retinopathy of prematurity (ROP) is one of the leading causes of preventable blindness in children worldwide. Middle-income nations are currently experiencing epidemic levels of ROP, because greater access to neonatal intensive care units has improved survival rates of premature infants, but without...

Full description

Saved in:
Bibliographic Details
Published in:Digital journal of ophthalmology Vol. 25; no. 4; pp. 49 - 58
Main Authors: Bowe, Theodore, Nyamai, Lily, Ademola-Popoola, Dupe, Amphornphruet, Atchara, Anzures, Rachelle, Cernichiaro-Espinosa, Linda A, Duke, Roseline, Duran, Fahir, Martinez-Castellanos, Maria Ana, Multani, Prabhujot Kaur, Nitulescu, Cristina E, Padhi, Tapas Ranjan, Tipsuriyaporn, Boontip, Chan, R V Paul, Campbell, J Peter, Yonekawa, Yoshihiro
Format: Journal Article
Language:English
Published: United States Massachusetts Eye and Ear Infirmary 12-10-2019
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Retinopathy of prematurity (ROP) is one of the leading causes of preventable blindness in children worldwide. Middle-income nations are currently experiencing epidemic levels of ROP, because greater access to neonatal intensive care units has improved survival rates of premature infants, but without sophisticated oxygen regulation. The epidemiology, screening infrastructure, treatment options, and challenges that these countries face are often tied to unique local socioeconomic, cultural, geopolitical, and medical factors. We present an overview and narratives of the current state of ROP in eight countries that are or soon will be experiencing ROP epidemics-India, Kenya, Mexico, Nigeria, Phillipines, Romania, Thailand, and Venezuela-with a view to fostering both an understanding of the differences in the ROP landscape in various settings and an interest in the further development of ROP screening and treatment services tailored to local requirements.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Disclosures: Consultant for Alcon (RVPC, YY), Allergan (RVPC), Bausch & Lomb Surgical (RVPC), Visunex Medical Systems (RVPC).
Funding/support: Research to Prevent Blindness, New York, NY (RVPC). This project was supported by grants K12EY027720 and P30EY10572 from the National Institutes of Health, Bethesda, MD (JPC); by grants SCH-1622679 from the National Science Foundation, Arlington, VA (JPC); and by unrestricted departmental funding and a Career Development Award from Research to Prevent Blindness, New York, NY (JPC). Funding organizations had no role in the design of conduct of this project.
These authors contributed equally to this work as first authors.
ISSN:1542-8958
1542-8958
DOI:10.5693/djo.01.2019.08.002